Effects of LNG-IUS combined with TCRE on ovarian function, MMP and related factors in patients with adenomyosis

摘要

Objective: To observe the effect of combined therapy regimen on ovarian function, MMP andrelated factors in patients with adenomyosis under the condition of LNG-IUS drug therapy.Methods: A total of 110 patients with adenomyosis from October 2015 to October 2017 wereretrospectively analyzed and divided into control group and observation group. The controlgroup of 54 patients, observation group of 56 patients. All patients were treated with LNGIUSsystem in the 4th to 7th day of the menstrual cycle. The patients in the observation groupwere treated with TCRE on the basis of LNG-IUS. The fasting venous blood was taken fromthe third day of menstruation and the luteinizing hormone (LH (MMP-2, MMP-3, MMP-9)were detected by enzyme-linked immunosorbent assay (ELISA). The levels of VEGF, CA125and IGF-1 were detected by enzyme-linked immunosorbent assay (ELISA) Ang-2, PGE2levels were compared. Results: There was no significant difference in LH, FSH and E2levels between the two groups before treatment. After treatment, the levels of LH, FSH andE2 were significantly higher in the two groups compared with those before treatment. (2)Before treatment, the levels of serum MMP-2, MMP-3, MMP-2 and MMP-2 in the two groupswere significantly higher than those in the control group. The levels of MMP-2, MMP-3 andMMP-9 in the serum of the two groups were significantly lower than those before treatment,and there was no significant difference between the two groups. (3) Before treatment, serumlevels of VEGF, CA125, IGF-1, Ang-2 and PGE2 in the two groups were significantly lowerthan those in the control group. The levels of serum VEGF, CA125, IGF-1, Ang-2 and PGE2in the two groups were significantly lower than those before treatment. The patients in theobservation group were significantly lower than the control group, there was significantdifference between the two groups. Conclusion The levels of serum MMP-2, MMP-3, MMP-9and VEGF, CA125, IGF-1, Ang-2 and MMP-2 in patients with adenomyosis were treated withTCRE on the basis of LNG-IUS drug therapy. PGE2 level, indicating that TCRE combinedwith LNG-IUS drug therapy can not only improve the efficacy, improve the patient's menstrualflow, dysmenorrhea and other symptoms, control the progression of the disease, but also byregulating the expression of certain factors play a role in improving ovarian function, worthy ofclinical On the promotion and application.